Clinical updates on carvedilol: a first choice β-blocker in the treatment of cardiovascular diseases-Reference-Cited by-同舟云学术

Clinical updates on carvedilol: a first choice β-blocker in the treatment of cardiovascular diseases

Published:2010-01-14 Issue:2 Volume:6 Page:237-250
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Chakraborty Subhashis,Shukla Dali,Mishra Brahmeshwar,Singh Sanjay

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/17425250903540220

Reference94 articles.

1. Mathers C, Lopez A, Murray CJ. Global burden of disease and risk factors. Oxford University Press, New York; 2006

2. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

3. Leeder S, Raymond S, Greenberg H, A race against time: the challenge of cardiovascular disease in developing countries. Trustees of Columbia University, New York; 2004

4. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis

5. Heart rate as a treatable cardiovascular risk factor

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A HPLC-MS/MS method for the determination of Nadolol in rat plasma: Development, validation, and application to pharmacokinetic study;European Journal of Mass Spectrometry;2023-06

2. Preparation and physicochemical characterization of binary and ternary ground mixtures of carvedilol with PVP and SLS aimed to improve the drug dissolution;Pharmaceutical Development and Technology;2019-07-29

3. Labrasol-Enriched Nanoliposomal Formulation: Novel Approach to Improve Oral Absorption of Water-Insoluble Drug, Carvedilol;AAPS PharmSciTech;2018-07-20

4. Chemically modified carbon paste sensor for the potentiometric determination of carvedilol in pharmaceutical and biological media;Measurement;2015-01

5. Association of Common Polymorphisms in β1-adrenergic Receptor With Antihypertensive Response to Carvedilol;Journal of Cardiovascular Pharmacology;2014-10